 October 30, 2007 |
|
|
Is Once-Daily Kaletra an Effective Dosing Option?
An international study comparing Norvir (ritonavir)-boosted Prezista (darunavir) to Kaletra (lopinavir/ritonavir) in people starting treatment for the first time has reported a surprising secondary finding—better virologic control among patients with high pre-therapy viral loads using twice daily, as opposed to once daily, Kaletra.
|
|
| |
|
|
|
Pre-treatment CD4 Count Predicts CD4 Gains on Treatment
The higher a person’s CD4 count upon starting HIV treatment, the higher their CD4 count will be 60 months later, say British researchers at the 11th European AIDS Conference in Madrid.
|
|
| |
|
|
|
October 25, 2007 |
|
|
Strategies for Success With Kaletra Monotherapy
Two reports regarding the experimental use of Kaletra (lopinavir/ritonavir), without other medications, show that it can successfully keep HIV under control, and offer predictions regarding who will most likely benefit from the use of Kaletra monotherapy.
|
|
| |
|
|
|
More Promising Data on Selzentry for Drug-Resistant HIV
People taking Selzentry (maraviroc) had greater viral load reductions and CD4 count increases compared to those taking a placebo after 48 weeks in the MOTIVATE 2 study.
|
|
| |
|
|
|
 |
|
October 26, 2007 |
|
|
Rilpivirine Comparable to Sustiva in Treatment First-Timers
The experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine is comparable to Sustiva in terms of reducing HIV levels and increasing CD4 counts over 48 weeks in people taking antiretroviral treatment for the first time. |
|
| |
|
|
|
October 31, 2007 |
|
|
HIV Treatment Greatly Improves Brain Illness Survival
Combination antiretroviral (ARV) treatment has significantly increased survival in people diagnosed with AIDS-related illnesses of the brain, according to data presented at the 11th European AIDS Conference in Madrid. |
|
| |
|
|
|
October 27, 2007 |
|
|
Crestor Bests Pravachol for Elevated Lipids
Crestor is superior to Pravachol in HIV-positive people on antiretroviral therapy who experience LDL cholesterol and triglyceride elevations, according to new data presented at the 11th EACS in Madrid. |
|
| |
|
|
|
October 26, 2007 |
|
|
More Rash With Once-Daily Viramune
People who used Viramune once daily are more likely to stop treatment due to skin rashes than people who used it twice-a-day. |
|
| |
|
|
|
Tesamorelin (TH9507) Safe and Effective for 52 Weeks
HIV-positive patients with lipodystrophy can be treated safely and effectively with tesamorelin (TH9507) for at least 52 weeks, according to new data presented this week at the 11th European AIDS Conference in Madrid. |
|
| |
|
|
|
October 29, 2007 |
|
|
Small Steps Forward in HIV Prevention
Slow but steady progress is being made on several HIV prevention fronts, say researchers in a special symposium on HIV prevention at the 11th European AIDS Conference. |
|
| |
|
|
-->
|
|
|
October 27, 2007 |
|
|
New Menu of Antiviral Options
 Dr. José Gatell talks with David Evans about the latest treatment news on Selzentry, rilpivirine (TMC278) and the continued interest in Kaletra monotherapy.
|
|
| |
|
|
|
Children and Challenges: Treating Pediatric HIV
 Over 2 million children are living with HIV/AIDS throughout the world. Dr. José Ramos talks with Peter Staley about the unique challenges facing HIV-positive children and their health care providers.
|
|
| |
|
|
|
HIV and its medications may increase the risk of cardiovascular disease, but Dr. Jens Lundgren tells Peter Staley that there's a lot to be said for preventive strategies.
Want to have a baby? Dr. Valerie Stone checks in with David Evans about family planning for couples living with HIV.
Dr. Jonathan Schapiro tells Peter Staley that an undetectable viral load is almost always an obtainable goal, even for highly treatment-experienced patients with drug-resistant HIV.
